

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014

Granada, a 29 de mayo de 2014

HECHO RELEVANTE NEURON BIOPHARMA, S.A.

Muy Sres. Nuestros:

En cumplimiento con lo dispuesto en la Circular 9/2010 del MAB sobre información a suministrar por empresas en expansión incorporadas a negociación en el MAB, por la presente se pone en conocimiento la siguiente información relativa a Neuron Biopharma, S.A.

La Compañía ha participado en el 10º Foro Medcap de empresas de mediana capitalización, organizado por Bolsas y Mercados Españoles. Adjuntamos la presentación corporativa que se ha utilizado en dicho foro.

Atentamente,

D. Fernando Valdivieso Amate
Presidente del Consejo de Administración





Madrid
28 mayo 2014




NEURON
BIO



Structure: 2006-2013



Mission & Vision



Mission

Creation, development and management of biotechnological companies

Vision

To be recognized as an international reference in the medical biotechnology during the next five years



Overview

COMPANY PROFILE: Quoted on the **Spanish Alternative Stock Market (MAB)**

LOCATIONS:

- Granada Health-Science Technology Park (headquarters)
- Madrid Science Park (laboratory, animal facilities & offices)

BUSINESS LINES:

- Drug Discovery&Development
- Development of diagnostics tools
- R&D bioservices

MANAGEMENT:

- **UNE166.002** (Standard Operating Procedure for R&D)
- **SGE21** (Ethical and CSR Management System)

R&D:

- **More than 50 years of accumulated postdoctoral experience** in R&D
- Participation in 15 scientific projects
- Property of a wide **collection of molecules** (new chemical entities and reprofiling drugs) and natural products (>20.000 plant and microbial extracts)
- Over **€10 million so far invested** in R&D



Strengths



TEAM: 23 people on the staff, 10 of them doctors, a Board of Directors with wide business experience and an internationally recognized scientific advisory board

TECHNOLOGY: Exclusive **Drug Discovery & Development Platform** consisting in:

- A Screening Platform to identify potential neuroprotective candidates (high-throughput technologies)
- A Preclinical Platform to select the better in vivo candidate and perform its development and optimization
- More than 50 different technologies including in silico, in vitro and cellular assays as well as animal models
- Efficacy, safety and pharmacokinetics

MARKETS:


Global Central Nervous System (CNS) market: \$71 billion in 2010

- Neurodegenerative disorders market: >\$21 billion in 2009
- Alzheimer's disease (AD): \$8 billion in 2009 and \$9.6 billion in 2014 (expected)
- Drugs against AD: >\$4.2 billion in 2012
- Diagnostic tools against AD: \$1.2 billion in 2009 and \$2.9 billion in 2014 (expected)

Global R&D services market: \$85-105 billion in 2013

- Non-clinical research market: \$11-15 billion in 2013

Holding structure: 2014





- 1. COMPANY PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. KEY DIFFERENTIAL STRATEGY**
- 6. BUSINESS RISK
DIVERSIFICATION & CONTINGENCY
STRATEGIES:**
- 7. BUSSINESS MODEL**
- 8. NEXT STEPS**





1. COMPANY PROFILE: Public company quoting on the **Spanish Alternative Stock Market (MAB)**

2. MISSION: Creation, development and management of **biotech companies**

3. OPPORTUNITY DESCRIPTION:

- The global biotechnology market in 2016 is forecast to have a value of **>\$450 billion***
- Medical/healthcare is **the largest segment** of the global biotechnology market (67%)*
- Americas accounts for 45% of the global biotechnology market value*

4. SOLUTION PROPOSAL:

- Neuron Bio has been specialized in the last years in the biotech market, generating and developing new companies with an increasing value



5. KEY DIFFERENTIAL STRATEGY :

- **Hybrid strategy** (services for clients and generation of value for stakeholders)
- Holding structure with **several companies in the group**

6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- **Diversity** in the business lines
- Capacity to generate **new business**

7. BUSSINESS MODEL:

- **Sale of participations** of the subsidiary companies
- **Exploitation** of the Neuron Bio facilities and laboratories
- Sale of **services** for clients
- **Co-developments** with strategic partners

8. NEXT STEPS:

- 1) To move to the **new headquarters** (6 months)
- 2) To reach the **funding** for the subsidiary companies (12 months)
- 3) To increase the **visibility** of the group (12 months)

- 1. PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. BUSINESS MODEL**




- 1. PROFILE:** Neuron Bio trademark to commercialize R&D bioservices
- 2. MISSION:** To offer **integrated preclinical solutions** for pharmaceutical, biotechnology and agro-food companies
- 3. OPPORTUNITY DESCRIPTION:**
 - The global market for drug discovery & development is over **\$85 billion**
 - The **main therapeutic markets** are autoimmune diseases, Central Nervous System, cardiovascular, infection, obesity and oncology
 - In 2010, the US nutraceutical market stood at **\$50.4 billion** and was by far the largest nutraceutical market in the world




4. SOLUTION PROPOSAL:

- An exclusive **Screening & Preclinical Platform** to study efficacy, safety and pharmacokinetics of molecules, extracts, ingredients, and natural products
- More than **50 different technologies** including *in silico*, *in vitro*, cellular assays and animal models (zebrafish and rodents)



- 5. BUSSINESS MODEL:** Offer solutions to agrofood, biotech and pharma companies in two different business lines:
- **R&D Services:** efficacy, safety, pharmacokinetics&pharmacodynamics, generation of experimental models, etc.
 - **Consulting:** management, laboratory design, training, communication, industrial property, fundraising, etc.





- 1. COMPANY PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. KEY DIFFERENTIAL STRATEGY**
- 6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:**
- 7. BUSSINESS MODEL**
- 8. NEXT STEPS**




1. COMPANY PROFILE: Private company

2. MISSION: Discovery and development of compounds for prevention or treatment of neurodegenerative and **central nervous system diseases**

3. OPPORTUNITY DESCRIPTION:

- More than **44 million people** suffer from neurodegenerative disorders
- The global economic cost for Alzheimer's disease (AD) is **\$640 billion**
- The drug market for AD exceeded **\$4.2 billion** in 2012
- There are **not effective treatments** against AD





5. KEY DIFFERENTIAL STRATEGY TO ADDRESS ALZHEIMER'S DISEASE:

- Development of molecules with **more than one mechanism-of-action**
- Search for **disease-modifier** therapies focused on the **early stages** of the disease
- **Translational research** to reduce attrition in clinical trials
- Identification of **novel mechanisms of neuroprotection** to design new therapeutic strategies

6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- **Diversity** in the drug pipeline
- Availability of **back-up molecules** in each pharmacological group
- Development of neuroprotective compounds aimed at **different neurological disorders**, not only AD
- Molecules with **additional properties** to neuroprotection
- Feasible identification of **new candidates** and easily and fast preclinical development




7. BUSSINESS MODEL:

- Sale of exploitation licenses for the **neuroprotective compounds**
- Sale of use and exploitation licenses for the **Drug Discovery & Development platform** and compound evaluation

8. NEXT STEPS:

- 1) **NST0037** phase I (12 months)
- 2) Regulatory preclinical studies of **NST0076** or **NST0078** (18 months)
- 3) Preclinical efficacy studies of **NPS0163** (16 months)







1. COMPANY PROFILE

2. MISSION


3. OPPORTUNITY DESCRIPTION

4. SOLUTION PROPOSAL

5. KEY DIFFERENTIAL STRATEGY

6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES

7. BUSSINESS MODEL





1. COMPANY PROFILE: Private company

2. MISSION: Development of **diagnostic and prognostic tools** for human diseases with especial focus to neurological/neurodegenerative disorders

3. OPPORTUNITY DESCRIPTION:

- There are a **unmet diagnostic needs** for several human diseases, especially in the nervous disorders such as the Alzheimer's disease (AD)
- Diagnostic/biomarkers is the **2nd-largest segment** of the AD-market (\$2.9 billion in 2014)

4. SOLUTION PROPOSAL:

- Develop a **novel diagnostic tool** from early stages of AD
- Diagnostic tool that will identify **individuals with high risk** to develop AD



5. KEY DIFFERENTIAL STRATEGY TO ADDRESS ALZHEIMER'S DISEASE:

- Focused in the **discrimination** of individuals with MCI, AD, or healthy
- **Minimally invasive** sample collection
- **Combination** of biological fluids (saliva, blood...)
- Biomarker-based tool on **various mechanisms-of-action**

6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- Additional approaches to **expand the range of biomarkers** to analyze
- Identification of biomarker **for other dementias**
- To offer **diagnostics services** using our biomarker analysis platform and medical network

7. BUSSINESS MODEL: Sale of exploitation licenses for the discriminatory tool for:

- **Big Pharma Companies**
- **Diagnostics Companies**



Avda. Innovación nº1
Granada 181016 (Spain)
Tel. [+34] 958 750 598
iburgos@neuronbio.com



www.neuronbio.com
www.neuronbiopharma.com
www.neuronbioservices.com

